Could a brain lipid injection ease Parkinson's motor swings?

NCT ID NCT07585565

Not yet recruiting Disease control Sponsor: Qilu Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests an injectable drug called GM1 in 276 people with Parkinson's disease who experience motor fluctuations (times when medication wears off). Participants are randomly assigned to receive GM1 or a placebo for about 12 weeks, while continuing their usual Parkinson's medications. The goal is to see if GM1 can increase the time they feel good movement control without troublesome involuntary movements.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GM1 (monosialotetrahexosylganglioside sodium injection)
What this could lead to: If successful, this could provide a new option to help Parkinson's patients spend more time with good movement control and fewer side effects.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply broadly. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON'S DISEASE

More trials for these conditions

Other studies related to the condition(s) this trial covers.